Congestive Heart Failure
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes shortness of breath and fatigue (tiredness), and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.
Congestive Heart Failure Epidemiology Segmentation in the 7MM
- Prevalent Population of Heart Failure
- Diagnosed Prevalent Population of Heart Failure
- Gender-specific diagnosed prevalent cases of Heart Failure
- Age-specific diagnosed prevalent cases of Heart Failure
- NYHA class-specific diagnosed prevalent case
- Diagnosed prevalent cases of Heart Failure with Ejection Fraction
- Diagnosed Prevalent cases of Heart Failure associated with comorbidities
Congestive Heart Failure Epidemiological Insights Observed in the 7MM
- The total incident cases of Congestive Heart Failure observed in the 7MM were observed to be 16.6 million in the year 2021
Congestive Heart Failure Market Insight
The market size of Congestive Heart Failure in the 7MM was found to be approximately USD 7,412 Million in 2021. Whereas the market size in the US was found to be approximately USD 4,484 million in 2021.
The market size of the EU5 was found to be USD 2,582 million in the year 2021. However, the market size of Japan was found to be USD 346 million in 2021.
Congestive Heart Failure Market Strengths
The emergence of several therapies with mechanisms such as SGLT1 and SGLT2 inhibitors, vasopressin V2-receptor antagonists, cardiac myosin activators, myeloperoxidase inhibitor, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, etc., along with cell therapies in the upcoming market of HF.
Congestive Heart Failure Market Opportunities
Recent approvals of Verquvo, Jardiance, and Farxiga have given a ray of hope to other key players that developing therapies for CHF that could give fair competition to the existing approved and off-label therapies and take up a good share of the market.
Congestive Heart Failure Emerging Drugs
The emerging drugs in the Congestive Heart Failure market are
- Rexlemestrocel-L (Revascor)
- Finerenone (Kerendia)
- Semaglutide 2.4 mg
- Furoscix (furosemide injection)
- HNO (Nitroxyl) Donor (BMS-986231)
- Lenrispodun (ITI - 214)
- CardiAMPCell Therapy
Congestive Heart Failure Key Players
The key players working in the Congestive Heart Failure market are
- Otsuka Pharmaceutical
- Novo Nordisk
- Lexicon Pharmaceuticals
- Bristol-Myers Squibb
- Intra-Cellular Therapies
- Tenax Therapeutics
- Eli Lilly and Company